01 1Cipla
01 1ISAVUCONAZONIUM SULFATE
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2024-01-26
Pay. Date : 2023-12-13
DMF Number : 39151
Submission : 2023-12-18
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is ISAVUCONAZONIUM SULFATE, with a corresponding US DMF Number 39151.
Remarkably, this DMF maintains an Active status since its submission on December 18, 2023, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 26, 2024, and payment made on December 13, 2023, indicating their dedication to facilitating drug approvals, Categorized as Type II
